Newsroom Bayer

September
28,
2023
| 08:29 AM Europe/Amsterdam

Bayer to present new aflibercept 8 mg 60-week and 96-week data for patients with neovascular (wet) age-related macular degeneration and diabetic macular edema

Not intended for U.S. and UK Media – The European Society of Retina Specialists (EURETINA) Annual Meeting:

Presentations at EURETINA capture 60-week data, a key secondary endpoint, and two-year data (96-week) from the pivotal PULSAR and PHOTON clinical trials that provide insights into durability of extended treatment intervals as well as efficacy and
September
27,
2023
| 13:59 PM Europe/Amsterdam

Bayer to present latest real-world evidence of menopausal symptoms and their treatment

Not intended for UK Media – The Menopause Society Annual Meeting 2023:

Real-world evidence (RWE) research results on treatment utilization and pathways in women with menopausal symptoms via poster presentations on the CHAPTER natural menopause study, CHAPTER i-menopause study and REALISE study / These poster
September
21,
2023
| 14:29 PM Europe/Amsterdam
Strategic expansion of Bayer’s portfolio in breast imaging / Companies to deliver innovative solutions on contrast-enhanced mammography (CEM) to imaging facilities / Collaboration to include education and hands-on training to support the safe and
September
21,
2023
| 10:59 AM Europe/Amsterdam
Agreement with UK-based NIAB to acquire their strawberry pipeline and commercial portfolio / Focus on large-scale professional strawberry growers to meet growing consumer and retail demand / The program will continue to be based in Kent,
September
21,
2023
| 08:59 AM Europe/Amsterdam
Climate impacts estimated to have reduced farmer incomes by 15.7% on average over the past two years / Most pressing short-term challenges dominated by economic uncertainty and cost concerns / Yet 4 in 5 farmers have already taken or plan to take
September
21,
2023
| 08:29 AM Europe/Amsterdam
The investment supports Bayer’s sustainability goal to help provide 100 million women in low- and middle-income countries with access to modern contraception by 2030 / The company’s facility in Turku will utilize automation, robotics, and digital
September
20,
2023
| 17:59 PM Europe/Amsterdam

Bayer issues 1.75 billion euro hybrid bond

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

New issue of two tranches with a non-call period of 5.25 and 8.25 years, respectively, combined with a tender offer for two of Bayer’s existing hybrid bonds
September
19,
2023
| 08:59 AM Europe/Amsterdam
Leverkusen, September 19, 2023 – Dr. Jost Reinhard will take over as head of Bayer AG’s Investor Relations department effective October 1, 2023. The 51-year-old is currently responsible for Bayer’s Cell and Gene Therapy unit in the United States.
September
18,
2023
| 08:59 AM Europe/Amsterdam
Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors / Major milestone for Vividion’s chemoproteomics innovative technology platform /
August
30,
2023
| 14:59 PM Europe/Amsterdam

Bayer to invest EUR 220 million in new R&D facility at its Monheim site

Strong commitment to modern Crop Protection made in Europe:

Largest single investment in Crop Protection in Germany for 40 years / Focus on Environmental and Human Safety / State-of-the-art lab building and greenhouse / 5 floor main building; 28,000 m gross floor area / R&D facility offers space for 200
August
29,
2023
| 13:59 PM Europe/Amsterdam
New agreement will focus on CRISPR applications for Bayer’s Preceon™ Smart Corn System / Collaboration builds on successful initial gene-editing partnership between the two companies that resulted in 27 novel traits being transferred into Bayer’s

Sign up for our Newsletter

We will keep you informed about the latest news.